Systemic lupus erythematosus: An update on current pharmacotherapy and future directions

Expert Opinion on Biological Therapy

Volumn 13, Issue 5, 2013, Pages 723-737

  Touma, Zahi ^a   Urowitz, Murray B ^b   Gladman, Dafna D ^a  

^a TORONTO WESTERN HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Biological therapy; Lupus; Lupus pharmacotherapy; Systemic lupus erythematosus

Indexed keywords

ABATACEPT; ABETIMUS; ANTINUCLEAR ANTIBODY; AZATHIOPRINE; BELIMUMAB; CYCLOPHOSPHAMIDE; EPRATUZUMAB; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISONE; RITUXIMAB; TORALIZUMAB;

BINDING AFFINITY; DISEASE ACTIVITY; DOSE RESPONSE; DRUG APPROVAL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; GLOMERULUS FILTRATION RATE; HEALTH CARE QUALITY; HEMATURIA; HUMAN; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE PROLIFERATION; MAINTENANCE THERAPY; MULTIPLE CYCLE TREATMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PROTEINURIA; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CLINICAL TRIALS AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; IMMUNOCONJUGATES; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MYCOPHENOLIC ACID; QUALITY OF LIFE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84876052033     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2013.764411     Document Type: Review

References (58)

1. Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012;64:1215-26
2. Wofsy D, Hillson JL, Diamond B. Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions. Arthritis Rheum 2012; Epub ahead of print
3. Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010;62:222-33
4. Francis L, Perl A. Pharmacotherapy of systemic lupus erythematosus. Expert Opin Pharmacother 2009;10:1481-94
5. Navarra SV, Guzman RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011;377:721-31
6. Smolen JS, Strand V, Cardiel M, et al. Randomized clinical trials and longitudinal observational studies in systemic lupus erythematosus: consensus on a preliminary core set of outcome domains. J Rheumatol 1999;26:504-7
7. Touma Z, Gladman DD, Murray MB. Clinical measures, metrics, and indices. In: Wallace DJ, Hahn BH, editors. Dubois' lupus erythematosus. 8th edition. Lippincott Williams & Wilkins, Saunders; 2012
8. Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992;35:630-40
9. Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002;29:288-91
10. Petri M, Kim MY, Kalunian KC, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005;353:2550-8
11. Hay EM, Bacon PA, Gordon C, et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 1993;86:447-58
12. Isenberg DA, Rahman A, Allen E, et al. BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus. Rheumatology (Oxford) 2005;44:902-6
13. Touma Z, Gladman DD, Urowitz MB, et al. Mycophenolate mofetil for induction treatment of lupus nephritis: a systematic review and metaanalysis. J Rheumatol 2011;38:69-78
14. Furie RA, Petri MA, Wallace DJ, et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum 2009;61:1143-51
15. McHorney CA, Ware JE Jr, Lu JF, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care 1994;32:40-66
16. McElhone K, Abbott J, Shelmerdine J, et al. Development and validation of a disease-specific health-related quality of life measure, the LupusQol, for adults with systemic lupus erythematosus. Arthritis Rheum 2007;57:972-9
17. Touma Z, Gladman DD, Ibanez D, Urowitz MB. Is there an advantage over SF-36 with a quality of life measure that is specific to systemic lupus erythematosus? J Rheumatol 2011;38:1898-905
18. Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) 2012;64:797-808
19. Baker KP, Edwards BM, Main SH, et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum 2003;48:3253-65
20. FDA approves Benlysta to treat lupus. FDA news release, 2011. Available from: http://www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/ ucm246489.htm [Last accessed 30 October 2012]
21. Health Canada's Summary Basis of Decison for Benlysta, 2011. Available from: http://www.hc-sc.gc.ca/dhp-mps/ alt-formats/pdf/prodpharma/sbd-smd/ drug-med/ sbd-smd-2011-benlysta-137699-eng.pdf [Last accessed 30 October 2012]
22. Wallace DJ, Stohl W, Furie RA, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 2009;61:1168-78
23. Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011;63:3918-30
24. Manzi S, Sanchez-Guerrero J, Merrill JT, et al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis 2012;71:1833-8
25. van Vollenhoven RF, Petri MA, Cervera R, et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis 2012;71:1343-9
26. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-81
27. Touma Z, Urowitz MB, Ibanez D, GLadman DD. Effect of partial and complete recovery in lupus nephritis on long term outcomes [abstract 841]. Arthritis Rheum 2012; In press
28. Touma Z, Gladman DD, Ibanez D, Urowitz MB. Development and initial validation of the systemic lupus erythematosus disease activity index 2000 responder index 50. J Rheumatol 2011;38:275-84
29. Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009;20:1103-12
30. Dorner T, Kaufmann J, Wegener WA, et al. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther 2006;8:R74
31. Wallace DJ, Kalunian KC, Petri MA, et al. Epratuzumab demonstrates clinically meaningful improvements inpatients with moderate to severe systemic lupus erythematosus (SLE): results from EMBLEM, a phase IIb study. Arthritis Rheum 2010;62(Suppl 10):1452
32. Study of epratuzumab versus placebo in subjects with moderate to severe general systemic lupus erythematosus (EMBODY 1). Available from: http://clinicaltrials. gov/ct2/show/NCT01262365? term= epratuzumab+and+lupus&rank=2 [Last accessed 30 October 2012]
33. Hobbs K, Wallace DJ, Strand V, et al. Safety and efficacy of epratuzumab in an open-label extension study (SL0006) [abstract 639]. Arthritis Rheum 2012; In press
34. Strand V, Palo Alto C, Hobbs K, et al. Epratuzumab-treated systemic lupus erythematosus patients report improvements in health-related quality of life: final results from an open-label extension study (SL0006) [abstract 2252]. Arthritis Rheum 2012; In press
35. Merrill JT, Burgos-Vargas R, Westhovens R, et al. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010;62:3077-87
36. Furie R, Nicholls K, Cheng TT, et al. Efficacy and safety of abatacept over 12 months in patients with lupus nephritis: results from a multicenter, randomized, double-blind, placebo-controlled phase II/III study. Arthritis Rheum 2011;63(Suppl):2469
37. Abatacept and cyclophosphamide combination therapy for lupus nephritis (ACCESS). Available from: http:// clinicaltrials.gov/ct2/show/ NCT00774852?term=access&rank=21 [Last accessed 30 October 2012]
38. Touma Z, Gladman DD, Tulloch-Reid D, et al. Burden of autoantibodies and association with disease activity and damage in systemic lupus erythematosus. Clin Exp Rheumatol 2010;28:525-31
39. Horowitz DM, Furie RA. Abetimus sodium: a medication for the prevention of lupus nephritis flares. Expert Opin Pharmacother 2009;10:1501-7
40. Alarcon-Segovia D, Tumlin JA, Furie RA, et al. LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study. Arthritis Rheum 2003;48:442-54
41. Cardiel MH, Tumlin JA, Furie RA, et al. Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trial. Arthritis Rheum 2008;58:2470-80
42. Linnik MD, Tansey MJ, Joh T. Dose dependent reduction in anti-dsDNA antibody levels observed with abetimus sodium through 52 weeks in the phase 3 ASPEN Study (Abetimus sodium in patients with a history of lupus nephritis). Arthritis Rheum 2008;58(Suppl):1077
43. Kalunian KC, Davis JC Jr, Merrill JT, et al. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:3251-8
44. Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005;353:2219-28
45. Chan TM, Tse KC, Tang CS, et al. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005;16:1076-84
46. Ong LM, Hooi LS, Lim TO, et al. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrology 2005;10:504-10
47. Dooley MA, Jayne D, Ginzler EM, et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 2011;365:1886-95
48. Houssiau FA, D'Cruz D, Sangle S, et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis 2010;69:2083-9
49. Guidance for Industry. Systemic lupus erythematosus-developing medical products for treatment. Available from: http://wwwfdagov/downloads/Drugs/ GuidanceComplianceRegulatory Information/Guidances/ucm072063pdf [Last accessed 30 October 2012]
50. Touma Z, GLadman DD, Ibanez D, et al. Lupus disease activity does not improve significantly in one system and worsen in another system. Arthritis Rheum 2011;63(Suppl 10):1386
51. Touma Z, Urowitz MB, Gladman DD. SLEDAI-2K for a 30-day window. Lupus 2010;19:49-51
52. Touma Z, Gladman DD, Ibanez D, et al. Systemic Lupus Erythematosus Disease activity index 2000 Responder Index-50 enhances the ability of SLE Responder Index to identify responders in clinical trials. J Rheumatol 2011;38:2395-9
53. Touma Z, Urowitz MB, Taghavi-Zadeh S, et al. Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index 50: sensitivity to response at 6 and 12 months. Rheumatology (Oxford) 2012;51:1814-19
54. Tsakonas E, Joseph L, Esdaile JM, et al. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. Lupus 1998;7:80-5
55. Tang C, Godfrey T, Stawell R, Nikpour M. Hydroxychloroquine in lupus: emerging evidence supporting multiple beneficial effects. Intern Med J 2012; Epub ahead of print
56. Petri M, Pike MC, Kelley L, et al. Systemic lupus erythematosus responder index assessment of responders in EMBLEM, a Phase IIb study in patients with moderate to severe systemic lupus erythematosus. Arthritis Rheum 2011;63(Suppl 10):1378
57. Touma Z, Gladman DD, Mackinnon A, et al. Development and assessment of users' satisfaction of the systemic lupus erythematosus disease activity index 2000 Responder Index-50 (S2K RI-50) website. J Rheumatol 2012; In press
58. Pike MC, Kelley L. Data quality challenges in systemic lupus erythematosus trials: how can this be optimized? Curr Rheumatol Rep 2012;14:324-33